Latest News

Indian shares rise on Gulf Peace Deal Tracking Global Rally

Indian shares closed higher Monday as they followed a global rally. Oil prices fell after the U.S. announced that it and Iran had reached a preliminary 'agreement' to end the conflict and resume traffic along the Strait of Hormuz.

Shehbaz Sherif, the Pakistani Prime Minister, who served as a facilitator in these negotiations, announced that two parties will sign a Memorandum of Understanding in Switzerland this Friday.

Investors can now find comfort in the fact that Iran's war is nearing its end, according to Gaurav Bhandari. Chief executive officer of Monarch Networth Capital.

The benchmark Nifty?50 index rose 0.98%, to 23,853.90. Meanwhile, the BSE Sensex gained 0.97%, to 76264.33. Both gained about 3% and?3.3% respectively in two sessions.

Gaurav Bhandari believes that Indian equities could have a good four to six months if monsoon risks recede. He expects Nifty 50 benchmark to reach the range of 27,000-28,000 by the end of the year. The index is down 8.7% for the year.

The rupee rose 0.41%, or 94.71 dollars per Indian 10-year bond.

Monarch's Bhandari stated that the $30 billion record of foreign outflows could begin to reverse with the recent RBI measures stabilising the rupee and inflation remaining under control.

Fourteen out of the 16 major sectors rose. The small-caps and the mid-caps, on a broader scale, rose by 1.1% and 1,3% respectively.

Larsen & Toubro, a major infrastructure company with significant exposure to the Middle East in terms of revenue, has gained 3%.

Asian markets rose 2.7% while Brent crude fell 5.2% to $82.8 per barrel, its lowest price since March.

India's lower oil prices, which are the third largest?oil exporter in the world, help to ease the pressure on the rupee, inflation and India's trade deficit.

Oil-sensitive stocks rose, including refiners BPCL and HPCL, cement makers UltraTech Cement and ACC, tyre companies?MRF and CEAT, as well as?airline IndiGo.

Aurobindo Pharma's stock fell by 4.7% after the U.S. Drug regulator raised serious concerns about its facility in Telangana.

(source: Reuters)